![]() ![]() 3 We conclude that, contrary to what many commentators suggest, government policy responses to pandemic threats that rely primarily on increasing private market incentives within our existing pharmaceutical markets are unlikely to yield pandemic treatments that meet public healthcare needs. The essay then follows the trajectory of the drug remdesivir as a case study that illustrates the consequences of relying on profit-driven pharmaceutical research and development (R&D) models for pandemic preparedness and response. The essay begins by explaining why the design of pharmaceutical markets in the USA yields suboptimal and sometimes even negative health outcomes. 2 In this essay, written as the COVID-19 pandemic unfolds, we illustrate how this divergence of private incentives from public health needs widens in contexts of pandemic preparedness and pandemic response. ![]() 1 In previous work we have shown how characteristics of healthcare markets in the USA create a divergence between the private incentives of for-profit companies and public health needs, leading to suboptimal health outcomes in what is a uniquely market-driven healthcare system. The problems are particularly pronounced in pharmaceutical markets, where we are pinning our hopes for both cures and vaccines. The longstanding problems of relying on a market response to a pandemic are becoming readily apparent in the USA, which has quickly become the epicenter of the coronavirus disease 2019 (COVID-19) outbreak.
0 Comments
Leave a Reply. |